North Wales Biotech Announces Licensing Opportunities for New Sepsis Related Diagnostic Test

North Wales medical device developer, J R Biomedical, based at the OpTIC Technology Centre in St Asaph, has developed a 10 minute test for the detection of a novel innate immune system biomarker with applications in the diagnosis of sepsis.

Dr Rees, founder and director of J R Biomedical said, “We have worked closely with Cardiff University to develop a rapid test for soluble Toll-like receptor 2 (sTLR2), which has the potential to provide further information for clinicians, in addition to traditional biomarkers of sepsis such as C-reactive protein (CRP) and procalcitonin (PCT). During the R&D phase of the rapid test we also developed a portfolio of proprietary antibodies that react specifically with sTLR2, which can be used in a wide range of immunoassay systems and detection methods, either commercially or for research purposes.”

The company has filed a UK patent application for the device, is UKCA certified, and assembled at their ISO13485:2016 facility in St Asaph.

J R Biomedical will be exhibiting the sTLR2 RAPID test at MEDICA in November, 2025 as part of the Welsh Government delegation in Düsseldorf.

For further information on licensing and distribution opportunities for the sTLR2 RAPID test or antibody portfolio, please see https://imiwn.com

Exhibitor Data Sheet